Acute myeloid leukemia (AML), a serious haematological cancer, remains a disease often defined by poor prognosis. However, less than 30% of diagnosed incident cases of AML are considered of adverse risk, according to GlobalData, a leading data analytics company.
The company’s latest report, ‘Acute Myeloid Leukemia: Epidemiology Forecast to 2029’, reveals that by 2029, there will be more than 90,000 diagnosed incident cases of AML in the eight major markets (8MM*), up from 72,000 cases in 2019, with roughly 28% of those cases falling into the category of adverse prognostic risk.
Topias Lemetyinen, MPH, Managing Epidemiologist at GlobalData, said: “Although AML is defined by its poor prognosis, more than 70% of cases are diagnosed at a favorable or intermediate risk, meaning that early intervention may offer a chance for treatment response. Despite the growth in diagnosed incident cases of AML cases in the 8MM from 2019 to 2029, it is not expected that any major changes will be seen in the prognostic risk groups.
“Urban China is expected to have the highest number of diagnosed incident cases of AML from 2019 to 2029, with more than 29,500 cases diagnosed in 2019, largely driven by the size of the population.”
*8MM: US, France, Germany, Italy, Spain, UK, Japan, Urban China